Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Lucia Del Mastro, Alessandra Fabi et al.|EClinicalMedicine|2023Cited by 28
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2022Cited by 6
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III TrialDomenica Lorusso, Giovanni Scambia, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2024Cited by 3